Hong, David S <br/><br/>
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.  [electronic resource] 

 -  The Lancet. Oncology  May 2014 
 - 656-66 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(14)70155-X  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Interleukin-1alpha--antagonists & inhibitors<br/>Kaplan-Meier Estimate<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Treatment Outcome